The U.S. Solicitor General has filed an amicus brief taking the side of two pharmaceutical sales reps in the overtime case that they filed against GlaxoSmithKline.
Missing documents allegedly kept a review of Tamiflu from conclusively examining the drug’s efficacy. Are reviews marred by publication and reporting biases? What can be done to make assessments more robust?
Open-access research project F1000 has launched a program in which submissions are published following an “initial sanity check” from the project’s director of new product development
Media Choice—March 2012
March 1, 2012
5:00 am
Glenn Kolansky, Board Certified Dermatologist, Adv. Dermatology Surgery & Laser Center, Red Bank, NJ.